BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Equities research analysts at William Blair lowered their Q3 2017 EPS estimates for BioMarin Pharmaceutical in a research report issued to clients and investors on Thursday. William Blair analyst T. Lugo now expects that the biotechnology company will earn ($0.27) per share for the quarter, down from their previous estimate of ($0.06). William Blair also issued estimates for BioMarin Pharmaceutical’s Q4 2017 earnings at ($0.16) EPS and FY2018 earnings at ($0.45) EPS.

Several other brokerages have also issued reports on BMRN. Sanford C. Bernstein started coverage on BioMarin Pharmaceutical in a research report on Thursday, July 27th. They set a “market perform” rating and a $89.00 target price for the company. Evercore ISI started coverage on BioMarin Pharmaceutical in a research report on Wednesday, August 16th. They set an “outperform” rating and a $100.00 target price for the company. Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and set a $129.00 target price on shares of BioMarin Pharmaceutical in a research report on Friday, October 6th. Royal Bank Of Canada started coverage on BioMarin Pharmaceutical in a research report on Thursday, September 14th. They set a “sector perform” rating and a $93.00 target price for the company. Finally, SunTrust Banks, Inc. reaffirmed a “buy” rating and set a $115.00 target price on shares of BioMarin Pharmaceutical in a research report on Friday, July 14th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and sixteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $111.25.

ILLEGAL ACTIVITY WARNING: “Brokers Issue Forecasts for BioMarin Pharmaceutical Inc.’s Q3 2017 Earnings (BMRN)” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/23/brokers-issue-forecasts-for-biomarin-pharmaceutical-inc-s-q3-2017-earnings-bmrn.html.

BioMarin Pharmaceutical (BMRN) opened at 87.75 on Monday. The firm’s 50-day moving average is $92.50 and its 200-day moving average is $90.06. BioMarin Pharmaceutical has a 52-week low of $78.42 and a 52-week high of $100.51. The company’s market capitalization is $15.38 billion.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.01. BioMarin Pharmaceutical had a negative net margin of 15.54% and a negative return on equity of 5.77%. The business had revenue of $317.50 million during the quarter, compared to analysts’ expectations of $311.41 million. During the same period last year, the business earned ($2.61) earnings per share. The firm’s revenue was up 5.8% on a year-over-year basis.

In other news, insider Henry J. Fuchs sold 15,000 shares of BioMarin Pharmaceutical stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $90.50, for a total transaction of $1,357,500.00. Following the completion of the sale, the insider now owns 141,422 shares in the company, valued at approximately $12,798,691. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director V Bryan Lawlis sold 3,750 shares of BioMarin Pharmaceutical stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $91.26, for a total value of $342,225.00. Following the sale, the director now owns 19,660 shares of the company’s stock, valued at approximately $1,794,171.60. The disclosure for this sale can be found here. In the last quarter, insiders have sold 40,686 shares of company stock valued at $3,736,318. Corporate insiders own 1.85% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the company. Global X Management Co. LLC raised its holdings in shares of BioMarin Pharmaceutical by 59.7% during the 1st quarter. Global X Management Co. LLC now owns 1,656 shares of the biotechnology company’s stock valued at $145,000 after buying an additional 619 shares in the last quarter. Korea Investment CORP raised its holdings in shares of BioMarin Pharmaceutical by 143.5% during the 2nd quarter. Korea Investment CORP now owns 1,595 shares of the biotechnology company’s stock valued at $145,000 after buying an additional 940 shares in the last quarter. Toronto Dominion Bank raised its holdings in shares of BioMarin Pharmaceutical by 12.9% during the 2nd quarter. Toronto Dominion Bank now owns 2,124 shares of the biotechnology company’s stock valued at $193,000 after buying an additional 243 shares in the last quarter. Cambridge Investment Research Advisors Inc. purchased a new position in shares of BioMarin Pharmaceutical during the 2nd quarter valued at about $213,000. Finally, Cigna Investments Inc. New raised its holdings in shares of BioMarin Pharmaceutical by 1.5% during the 2nd quarter. Cigna Investments Inc. New now owns 2,377 shares of the biotechnology company’s stock valued at $216,000 after buying an additional 36 shares in the last quarter. Hedge funds and other institutional investors own 97.29% of the company’s stock.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

Earnings History and Estimates for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.